State of Wyoming Sells 4,576 Shares of Kymera Therapeutics, Inc. $KYMR

State of Wyoming lessened its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 38.8% during the 3rd quarter, Holdings Channel reports. The firm owned 7,204 shares of the company’s stock after selling 4,576 shares during the period. State of Wyoming’s holdings in Kymera Therapeutics were worth $805,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC increased its stake in Kymera Therapeutics by 27.5% during the 2nd quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock worth $52,000 after buying an additional 98 shares during the period. IFP Advisors Inc boosted its position in Kymera Therapeutics by 236.5% in the 3rd quarter. IFP Advisors Inc now owns 737 shares of the company’s stock valued at $82,000 after buying an additional 518 shares during the period. PNC Financial Services Group Inc. boosted its position in Kymera Therapeutics by 56.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,285 shares of the company’s stock valued at $107,000 after buying an additional 463 shares during the period. Empowered Funds LLC acquired a new position in shares of Kymera Therapeutics in the first quarter worth $203,000. Finally, Nykredit A S purchased a new stake in shares of Kymera Therapeutics during the second quarter worth $207,000.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Loop Capital set a $132.00 target price on Kymera Therapeutics in a report on Thursday. Deutsche Bank Aktiengesellschaft assumed coverage on Kymera Therapeutics in a research report on Thursday, July 30th. They issued a “hold” rating and a $120.00 price target on the stock. Morgan Stanley lifted their price objective on Kymera Therapeutics from $135.00 to $146.00 and gave the company an “overweight” rating in a research note on Tuesday, October 27th. Stifel Nicolaus boosted their price objective on Kymera Therapeutics from $132.00 to $152.00 and gave the stock a “buy” rating in a research report on Tuesday, September 22nd. Finally, Wall Street Zen lowered shares of Kymera Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $137.92.

Insider Activity

In other news, insider Brian Adams sold 6,371 shares of the firm’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $116.83, for a total transaction of $744,323.93. Following the sale, the insider owned 50,254 shares of the company’s stock, valued at approximately $5,871,174.82. This trade represents a 11.25% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $113.80, for a total value of $3,414,000.00. Following the sale, the chief executive officer owned 666,568 shares of the company’s stock, valued at approximately $75,855,438.40. The trade was a 4.31% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 15.98% of the company’s stock.

Kymera Therapeutics Trading Up 3.3%

Kymera Therapeutics stock opened at $126.63 on Friday. The company has a fifty day simple moving average of $114.93 and a 200-day simple moving average of $96.35. The stock has a market cap of $10.53 billion, a P/E ratio of -34.98 and a beta of 1.98. Kymera Therapeutics, Inc. has a 12-month low of $55.66 and a 12-month high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, October 29th. The company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.26) by ($0.06). Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 22.65%. The business had revenue of $1.35 million during the quarter, compared to analysts’ expectations of $3.28 million. During the same period last year, the company earned ($0.94) EPS. The business’s quarterly revenue was up .0% compared to the same quarter last year. As a group, sell-side analysts forecast that Kymera Therapeutics, Inc. will post -3.90 earnings per share for the current fiscal year.

Key Kymera Therapeutics News

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera reported positive Phase 1 results for KT-579, showing deep and sustained IRF5 degradation, strong modulation of disease-relevant biomarkers, and a favorable safety profile. The data support continued development of the company’s immunology pipeline. Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
• Positive Sentiment: Truist Financial reaffirmed its “buy” rating and raised its price target from $136 to $150, implying further upside based on the current trading level. Truist Securities Adjusts Price Target on Kymera Therapeutics
• Positive Sentiment: BTIG Research raised its target from $134 to $139 and maintained a “buy” rating, adding to the favorable analyst sentiment.
• Neutral Sentiment: Kymera provided a Phase 1 update on the formulation study for KT-621, offering investors additional information on the program’s ongoing clinical development. KT-621 Formulation Study Update
• Neutral Sentiment: RBC increased its price target from $112 to $116 but retained a “sector perform” rating, signaling limited conviction at the current valuation.
• Negative Sentiment: Third-quarter results missed expectations: adjusted loss was $1.32 per share versus a $1.26 consensus loss, while revenue of $1.35 million was below the $3.28 million estimate. The net loss also widened year over year, highlighting ongoing cash-burn and execution risks. Kymera Therapeutics Q3 Net Loss Widens

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell’s natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.

The company’s research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.